North Carolina Department of Health and Human Services
Division of Public Health • Epidemiology Section
Communicable Disease Branch



Patient's Last Name



Middle

ENCEPHALITIS, ARBOVIRAL, EEE
Confidential Communicable Disease Report—Part 2
NC DISEASE CODE: 97

First

#### ATTENTION HEALTH CARE PROVIDERS:

Please report relevant clinical findings about this disease event to the local health department.

Alias

Birthdate (mm/dd/yyyy)

SSN

REMINDER to Local Health Department staff: If sending this form to the Health Care Provider, remember to attach a cover letter from your agency indicating the part(s) of the form the provider should complete.

Maiden/Other

Suffix

NC EDSS Verify if lab results for this event are in NC EDSS. If not present, enter results.													
LAB RESULTS													
Specimen Date			Type of	f Test Test Result(s)		Description (comments)	Result I	Date	Lab Name—City/State				
/ /	1 1						1 1						
/ /	1 1						1 1						
1 1	1 1					/ /							
NC EDSS PART 2 WIZARD					CLINICAL FINDINGS				REASON FOR TESTING				
	UNICABLE DIS	EASE		EEG	EEG performed Y N U				Why was the patient tested for this condition?  ☐ Symptomatic of disease				
Is/was patient symptomatic for					Date performed (mm/dd/yyyy)://				Screening of asymptomatic person with reported				
this disease? Y N U				Result:				risk factor(s) ☐ Screening of asymptomatic person with					
If yes, symptom onset date (mm/dd/yyyy):/_/ CHECK ALL THAT APPLY:								no risk factor(s)					
Fever				Date performed (mm/dd/yyyy)://				Blood / organ / tissue donor screening					
Altered mental status				Result:				☐ Other ☐ Unknown					
Headache				Date performed (mm/dd/yyyy): / /					11				
Meningitis Y N U								Nov					
Encephalitis Y N U				Result:   Y				PREGNANCY					
Encephalomyelitis/ meningoencephalitis			Date performed (mm/dd/yyyy)://				Is the patient currently pregnant? Y N U						
Seizures/convulsions			Result:				Estimated delivery date (mm/dd/yyyy):// Is patient a post-partum mother						
Seizures/convulsions				Other symptoms, signs, clinical findings, or				(≤ 6 weeks)?					
Gait Disturbance			complications consistent with this illness				Did patient experience onset of symptoms within						
Dyscoordination Y N U Myoclonus Y N U			Specify:				6 weeks of delivery? ☐ Y ☐ N ☐ U						
Acute onset of	nerinheral			"	,-								
neuropathy Muscle weakne	oo (porocio)	H	N HU										
Please specify			N 🗆 0										
Localized Generalized													
Muscle paralysis ☐ Y ☐ N ☐ U Acute flaccid paralysis ☐ Y ☐ N ☐ U													
Asymmetric     Asymmetric								MATERNAL INFORMATION					
☐ Symmetric  Respiratory paralysis☐ Y ☐ N ☐ U								Was the child breastfed? ☐ Y ☐ N ☐ U Did the biologic mother ever have evidence of					
Did patient have CSF cell count?								serological IgG immunity?					
Did patient have CSF cell count? ☐ Y ☐ N ☐ U Result: ☐ Elevated ☐ Not elevated ☐ Unknown									Test date (mm/dd/yyyy)://				
								Result:					
									☐ Positive ☐ Negative ☐ Equivocal ☐ Unknown				

Patient's Last Name	First	Middle	Suffix	Maiden/Other	Alias	Birthdate (mm/dd/yyyy)	
						SSN	
HOSPITALIZATION INFORM	ATION		CARE FACILITY		<b>GEOGRAPHIC</b>	AL SITE OF EXPOSURE	
Was patient hospitalized for this illness >24 hours?	During the any of the Blood or Donated No Unknow Type of dor Date received	15 days prior to o following health or blood products (trd ova, sperm, organant recipient (tissue or nation/transplant_red (mm/dd/yyyy):	ransfusion) - recipient n, tissue, or bone marrow e/organ/bone/bone marrow	Specify location:  In NC  City  County  Outside NC, I  State  County  County  County	In what geographic location was the patient MOST LIKELY exposed?  Specify location:		
CLINICAL OUTCOMES		Once			Outside US		
Survived? Status at time of report: Fully recovered Survived but experiencing deficit from illness) at time Died? Died from this illness? Date of death (mm/dd/yyyy):_	sequelae (residual of report	Facility/pro Contact na Address City State Country	me at facility:	me period	Country  Unknown Is the patient par	rt of an outbreak of	
TRAVEL/IMMIGRATION		_	EXPOSURES		VACCINE		
The patient is:  Resident of NC Resident of another state or Foreign Visitor Refugee Recent Immigrant Foreign Adoptee None of the above Did patient have a travel histo 15 days prior to onset? List travel dates and destination From / to  Additional travel/residency inf	ory during the □Y □N □ Uns:	patient have to mosqui Exposed Until (mm Frequence Multil Daily City/county State of ex	on (mm/dd/yyyy):/_ //dd/yyyy):/_ y e ple times within thi	y for exposure	related to this d Vaccine type Unknown vac Date of administra Source of this vac	rior to illness onset was 1? 4 days ore	
		Was the pa Date of ir Medical red with provid Specify rea	nterview (mm/dd/y cords reviewed (ir ler/office staff)?	? Y N U yyy):// ncluding telephone revie Y N U cords were not reviewed			

# Encephalitis or Meningitis, Arboviral (includes California serogroup, Eastern equine, St. Louis, Western equine, West Nile, Powassan)

#### 2001 CDC Case Definition

## Clinical description

Arboviral infections may be asymptomatic or may result in illnesses of variable severity sometimes associated with central nervous system (CNS) involvement. When the CNS is affected, clinical syndromes ranging from febrile headache to aseptic meningitis to encephalitis may occur, and these are usually indistinguishable from similar syndromes caused by other viruses. Arboviral meningitis is characterized by fever, headache, stiff neck, and pleocytosis. Arboviral encephalitis is characterized by fever, headache, and altered mental status ranging from confusion to coma with or without additional signs of brain dysfunction (e.g., paresis or paralysis, cranial nerve palsies, sensory deficits, abnormal reflexes, generalized convulsions, and abnormal movements).

## Laboratory criteria for diagnosis

- Fourfold or greater change in virus-specific serum antibody titer, or
- Isolation of virus from or demonstration of specific viral antigen or genomic sequences in tissue, blood, cerebrospinal fluid (CSF), or other body fluid, or
- Virus-specific immunoglobulin M (IgM) antibodies demonstrated in CSF by antibody-capture enzyme immunoassay (EIA), or
- Virus-specific IgM antibodies demonstrated in serum by antibody-capture EIA and confirmed by demonstration of virus-specific serum immunoglobulin G (IgG) antibodies in the same or a later specimen by another serologic assay (e.g., neutralization or hemagglutination inhibition).

### Case classification

*Probable*: an encephalitis or meningitis case occurring during a period when arboviral transmission is likely, and with the following supportive serology: 1) a single or stable (less than or equal to twofold change) but elevated titer of virus-specific serum antibodies; or 2) serum IgM antibodies detected by antibody-capture EIA but with no available results of a confirmatory test for virus-specific serum IgG antibodies in the same or a later specimen.

Confirmed: an encephalitis or meningitis case that is laboratory confirmed

DHHS/EPI #97 JANUARY 2009